Fluorescence derivatization method for sensitive chromatographic determination of zidovudine based on the Huisgen reaction

Fluorescence derivatization method for sensitive chromatographic determination of zidovudine based on the Huisgen reaction

Accepted Manuscript Title: Fluorescence derivatization method for sensitive chromatographic determination of zidovudine based on the Huisgen reaction ...

259KB Sizes 0 Downloads 32 Views

Accepted Manuscript Title: Fluorescence derivatization method for sensitive chromatographic determination of zidovudine based on the Huisgen reaction Author: Yuki Maeda Naoya Kishikawa Kaname Ohyama Mitsuhiro Wada Rie Ikeda Naotaka Kuroda PII: DOI: Reference:

S0021-9673(14)00913-3 http://dx.doi.org/doi:10.1016/j.chroma.2014.06.017 CHROMA 355493

To appear in:

Journal of Chromatography A

Received date: Revised date: Accepted date:

1-5-2014 3-6-2014 3-6-2014

Please cite this article as: Y. Maeda, N. Kishikawa, K. Ohyama, M. Wada, R. Ikeda, N. Kuroda, Fluorescence derivatization method for sensitive chromatographic determination of zidovudine based on the Huisgen reaction, Journal of Chromatography A (2014), http://dx.doi.org/10.1016/j.chroma.2014.06.017 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1

Fluorescence derivatization method for sensitive chromatographic determination

2

of zidovudine based on the Huisgen reaction

3 Yuki Maeda, Naoya Kishikawa, Kaname Ohyama, Mitsuhiro Wada, Rie Ikeda and

5

Naotaka Kuroda

ip t

4

cr

6

Graduate School of Biomedical Sciences, Course of Pharmaceutical Sciences,

8

Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan

us

7

9

an

10 *Corresponding author: Naotaka Kuroda

12

Graduate School of Biomedical Sciences, Course of Pharmaceutical Sciences,

13

Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan

14

Phone: +81-95-819-2894

15

E-mail: [email protected]

M

11

Ac ce p

te

d

Fax: +81-95-819-2444

1

Page 1 of 23

16

Abstract

17 18

A novel pre-column fluorescence derivatization method for chromatographic analysis of azide compounds was developed based on the Huisgen reaction, which is a

20

specific cycloaddition reaction between an alkyne and an azide.

21

synthesized a fluorescent alkyne, 2-(4-ethynylphenyl)-4,5-diphenyl-1H-imidazole

22

(DIB-ET) as a reagent.

23

fluorophore and reactive center, respectively.

24

of DIB-ET, a high-performance liquid chromatography with fluorescence detection

25

method was developed for the determination of zidovudine as a model of azide

26

compound.

27

sulfate and L-ascorbic acid as catalysts, and the formed derivative was detected

28

fluorometrically.

29

of zidovudine in plasma samples with the detection limit of 0.28 ng mL-1 at a S/N = 3.

30

Finally, the proposed method could be applied to determine the zidovudine

31

concentration in rat plasma after administration of zidovudine without interference

33 34 35 36

cr

We designed and

DIB-ET has a lophine skeleton carrying an alkyne acting as

an

us

In order to evaluate the practicality

M

Zidovudine could be reacted with DIB-ET in the presence of copper (II)

te

d

The proposed method allows sensitive and selective determination

Ac ce p

32

ip t

19

from biological components.

Keywords: Huisgen reaction, Fluorescence derivatization, Azide group, Zidovudine, Fluorescent alkyne

2

Page 2 of 23

36

1. Introduction

37 38

It is important to understand the pharmacokinetics of drugs that can cause beneficial or adverse side effects even in small amounts.

40

analytical method is necessary to determine small amounts of drugs in biological

41

samples.

42

detection is a powerful analytical technique to determine drugs owing to its high

43

sensitivity and selectivity [1, 2].

44

fluorescence, derivatization reagents have been frequently adopted in order to convert

45

non-fluorescent drugs to strongly fluorescent derivatives.

46

of fluorescence derivatization reagents have been developed and applied for the

47

determination of small amounts of drugs in biological samples [3-7].

48

fluorescence derivatization reagents can easily react with co-existing biological

49

components and the resultant products can interfere with the detection of target drugs.

50

In order to overcome this problem, we have been attempted to develop a novel

51

fluorescence reagent that can react with target drug selectively even in the presence of

53 54 55 56

cr

High-performance liquid chromatography (HPLC) with fluorescence

us

But, since most drugs do not possess native

However,

d

M

an

Up to now, various types

te

Ac ce p

52

Therefore, a sensitive

ip t

39

biological components, based on specific chemical reactions.

We so far developed a

fluorescent aryl boronic acid, 4-(4,5-diphenyl-1H-imidazol-2-yl)phenylboronic acid (DPA, a lophine derivative) as a fluorescence derivatization reagent for aryl halides based on the Suzuki coupling reaction, which is a cross-coupling reaction between

aryl halides and aryl boronic acids [8-11].

It was found that DPA could react

57

selectively with aryl halide drugs such as haloperidol in the presence of biological

58

components.

59

4-(4,5-diphenyl-1H-imidazol-2-yl)iodobenzene, could be used as a specific

60

fluorescence derivatization reagent for alprenolol that has a terminal double bond

61

moiety based on the Mizoroki-Heck coupling reaction, which is a reaction between

Also, we recently reported that a lophine based fluorescent aryl iodide,

3

Page 3 of 23

62

aryl halides and terminal double bonds [12].

63

strategy, we attempted to develop a new type of specific fluorescence derivatization

64

reagent for azide group based on the Huisgen reaction. The Huisgen reaction [13-16] is a specific cycloaddition reaction between an

ip t

65

As an expansion of the analytical

66

alkyne and an azide in the presence of copper (I) as a catalyst to form stable

67

five-membered triazole ring [17].

68

representative reaction of click chemistry and is frequently used to build functional

69

molecules in various research fields.

70

reaction, we considered that fluorescent alkyne and fluorescent azide could be used as

71

specific derivatization reagent for azide group and alkyne moiety, respectively.

72

Huisgen reaction proceeds under mild conditions even in the presence of water, while

73

many general derivatization reactions often require hard conditions such as high

74

temperature and long reaction time, and are likely inhibited by water.

75

fluorescence derivatization reaction based on the Huisgen reaction should be suitable

76

for biomedical analysis.

77

fluorescent alkyne, 2-(4-ethynylphenyl)-4,5-diphenyl-1H-imidazole (DIB-ET) as a

79 80 81 82

cr

The

Therefore,

d

M

an

us

Owing to the high specificity of the Huisgen

te

From these aspects, we designed and synthesized a

Ac ce p

78

The Huisgen reaction is known as the most

specific fluorescence derivatization reagent for azide group (Fig. 1).

DIB-ET has a

lophine skeleton carrying an alkyne acting as fluorophore and reactive center, respectively.

In the present study, we applied DIB-ET to the development of

determination method for zidovudine as a model of azide compound.

Zidovudine is

an antiretroviral drug used for the treatment of human immunodeficiency virus (HIV)

83

infection [18, 19].

Since the adverse side effects of zidovudine, such as lactic

84

acidosis or myelosuppression were reported [20], the sensitive and selective

85

determination method for zidovudine should be useful to facilitate the safe dosing of

86

zidovudine.

87

derivative (DIB-zidovudine) after reaction with DIB-ET (Fig. 1), and DIB-zidovudine

We confirmed that zidovudine could be converted to fluorescent

4

Page 4 of 23

88

could be sensitively determined by HPLC with fluorescence detection.

Furthermore,

89

the developed method was successfully applied to the determination of zidovudine in

90

rat plasma after administration without any interference from biological components.

92

ip t

91 2. Experimental

95

2.1. Materials and reagents

Zidovudine was purchased from Tokyo Chemical Industries (Tokyo, Japan).

us

94

cr

93

96

Copper (II) sulfate, L-ascorbic acid, benzil and ammonium acetate were obtained from

97

Nacalai Tesque (Osaka, Japan).

98

Louis, MO, USA).

99

(Tokyo).

an

4-Ethynylbenzaldehyde was from Sigma (St.

Cellulose acetate membrane filter (0.45 µM) was from Advantec

M

Wistar male rats were obtained from Kyudo Experimental Animal

Laboratory (Saga, Japan).

DIB-ET and DIB-zidovudine were synthesized as

101

described in later sections.

Water was distilled and passed through a Pure Line

102

WL21P system (Yamato, Tokyo, Japan).

103

purity and quality available.

105 106 107 108

te

All other chemicals were of the highest

Stock solution of zidovudine was prepared in methanol

Ac ce p

104

d

100

and stored at 4 ºC.

DIB-ET, copper (II) sulfate and L-ascorbic acid dissolved in

methanol just before use.

2.2. Equipment

The HPLC system consisted of two Shimadzu LC-10AT pumps (Kyoto,

109

Japan), a Shimadzu RF-20Axs fluorescence detector, a Rheodyne (Cotati, CA, USA)

110

7125 injector with a 20-µL loop and Chromato-Pro chromatography data acquisition

111

system (Run Time Corporation, Kanagawa, Japan).

112 113

Fluorescence spectra were measured with a Shimadzu RF-1500 spectrofluorophotometer.

Mass spectral data were obtained with a JEOL

5

Page 5 of 23

114

JMS-700N spectrometer (Tokyo, Japan).

Elemental analyses were performed on a

115

Perkin Elmer 2400II (Norwalk, CT, USA).

116

Yanagimoto MP-53 melting point apparatus (Kyoto, Japan).

Melting points were measured with a

118

ip t

117 2.3. HPLC conditions

Chromatographic separation was performed on a Cosmosil 5C18-AR-II

cr

119

(250×4.6 mm i.d., Nacalai Tesque, Osaka, Japan) column with a gradient elution

121

program using solvent A (acetonitrile-5 mM Tris-HCl buffer (pH 7.4) (50:50, v/v%))

122

and solvent B (acetonitrile).

123

0% B (0–9.5 min), 0% B to 100% B linearly (9.5–10.0 min), and 100% B (10.0–19.0

124

min).

125

excitation and emission wavelength were set at 310 nm and 400 nm, respectively.

us

120

an

The gradient program was programmed as follows:

130 131 132 133 134 135

te

129

DIB-ET was synthesized according to the previous papers [12, 21].

Benzil

(157.5 mg, 0.75 mmol), ammonium acetate (500 mg, 6.5 mmol) and

Ac ce p

128

2.4. Synthesis of DIB-ET

d

126 127

The

M

The flow-rate was set at 1.0 mL min-1 at ambient temperature.

4-ethynylbenzaldehyde (97.5 mg, 0.81 mmol) were dissolved in 1.5 mL of acetic acid. This mixture was heated at 90 °C for 8 h. mixture was poured into cold water.

After cooling to room temperature, the

The resultant precipitate was obtained as

yellow crystals; yield: 191 mg, 78%, mp: 264 °C.

Elemental analysis; calculated for

C23H16N2: C, 86.22%; H, 5.03%, N, 8.74%, found: C, 86.17%, H, 5.00%, N, 8.82%.

FAB-MS (m/z) calculated: 321 [M+H]+, found 321.

136 137 138 139

2.5. Synthesis of authentic DIB-zidovudine DIB-ET (30.0 mg, 94 µmol), zidovudine (24.9 mg, 94 µmol), copper (II) sulfate (224.7 mg, 900 µmol) and L-ascorbic acid (159 mg, 900 µmol) were dissolved

6

Page 6 of 23

140

in 10 mL of tetrahydrofuran-water (50:50, v/v%).

After heating at 50 °C for 2 h, the

141

solution was evaporated and filtered.

142

mL of acetonitrile and water to give DIB-zidovudine as yellow crystals; yield: 28 mg,

143

51%, mp: 248-250 °C.

144

H, 4.97%, N, 16.68%, found: C, 67.57%, H, 5.22%, N, 16.89%. FAB-MS (m/z)

145

calculated: 588 [M+H]+, found 588.

The resulting precipitate was washed with 10

cr

ip t

Elemental analysis; calculated for C33H29N7 O4: C, 67.45%;

146

2.6. Fluorescent derivatization procedure for standard zidovudine

us

147

To 25 µL 0.32-1336 ng mL-1 zidovudine in methanol, 50 µL 4 mM DIB-ET in

148

methanol, 25 µL 40 mM copper (II) sulfate and 180 mM L-ascorbic acid in methanol

150

were successively added.

151

reduction of copper (II) sulfate with L-ascorbic acid.

152

reaction mixture was heated at 40 ºC for 5 min.

153

filter, a 20 µL of aliquot was injected into HPLC system.

157 158 159 160

M

d

After filtration through a membrane

2.7. Assay procedure for zidovudine in rat plasma Wistar male rats (240 ± 2 g) were anesthetized with ethyl carbamate (1.5 mg

kg-1).

Zidovudine administration was performed via right inguinal vein at a dose of

10 mg kg-1 [22].

Blood samples were collected through indwelling arterial catheters,

transferred to heparinized collection tubes and centrifuged at 2000×g for 10 min.

After centrifugation, the plasma was separated and stored at -80 °C in the dark until

161

analysis.

162

University Animal Care and Use Committee.

163

After vortex-mixing, the

Ac ce p

156

In this procedure, copper (I) was generated by the

te

154 155

an

149

The experiment was performed with an approval of the Nagasaki

Fifty microliters of methanol was added into 50 µL of plasma samples.

164

Then, samples were centrifuged at 5000×g for 10 min.

165

supernatant was collected and was subjected to the derivatization reaction as

7

Twenty-five microliters of

Page 7 of 23

166

previously described.

Pharmacokinetic parameters were determined by moment

167

analysis using a single-dose i.v. bolus drug administration model.

168

parameters were area under the curve (AUC), mean residence time (MRT), terminal

169

phase half life (T1/2), volume of distribution (Vd) and clearance (CL).

ip t

170 3. Result and discussion

cr

171 172

174

3.1. Fluorescence characteristics of DIB-ET and DIB-zidovudine

us

173

The studied

The fluorescence spectra of DIB-ET were measured in methanol and the maximum excitation and emission wavelengths of DIB-ET were found to be 310 and

176

400 nm, respectively.

177

wavelengths of DIB-zidovudine were almost identical to those of DIB-ET.

178

addition, the fluorescence intensity of DIB-zidovudine was almost identical to that of

179

same concentration of DIB-ET.

180

that the fluorescence characteristics of DIB-ET were not changed after the reaction

181

with zidovudine although the extension of the conjugation could be occurred by the

183 184 185 186

M

On the other hand, the maximum excitation and emission In

te

d

In view of results described above, it was suggested

Ac ce p

182

an

175

formation of triazole ring.

3.2. Optimization of fluorescent derivatization conditions Figure 2 (A) and (B) show typical chromatograms obtained from the reagent

blank and the reaction mixture of zidovudine with DIB-ET, respectively.

The peak

187

of DIB-zidovudine was detected at 8 min, while the excess DIB-ET was eluted later

188

than DIB-zidovudine and detected at approximately 15 min.

189

To obtain higher reactivity, the conditions used for the derivatization reaction

190

were optimized using a standard solution of zidovudine.

191

solvent on the reactivity was examined with methanol, tetrahydrofuran,

8

The effect of reaction

Page 8 of 23

192

N,N-dimethylformamide, 1-buthanol, ethanol and acetonitrile.

193

solvents, the optimal result was obtained with methanol (Fig. S1, supplementary

194

data).

195

methanol was selected as the reaction solvent.

196

investigated over a range of 0.5-6 mM and the maximum peak area of

197

DIB-zidovudine was obtained using 4 mM DIB-ET (Fig. 3A).

198

copper (II) sulfate was examined over a range of 10–120 mM, and the maximum and

199

constant peak area was obtained at a concentration over 30 mM (Fig. S2,

200

supplementary data); 40 mM copper (II) sulfate was selected.

201

concentration of L-ascorbic acid was examined over a range of 100-600 mM and 180

202

mM was selected because it gave maximum peak areas (Fig. S3, supplementary data).

203

The effects of reaction temperature and time were investigated (Fig. 3B).

204

almost same reactivity was obtained at temperature higher than 40 ºC, and the

205

maximum and constant reactivity was obtained for more than 5 min.

206

hand at room temperature, the reactivity was slightly reduced as compared with

207

heating.

209 210 211 212 213

In addition, since methanol can be used for the deproteinization of plasma,

ip t

The concentration of DIB-ET was

us

cr

The concentration of

The

On the other

te

d

M

an

The effect of

As a result, 40 °C and 5 min were chosen for the reaction temperature and

Ac ce p

208

Among these

time, respectively, because these conditions gave high and constant reactivity. Under the optimized conditions, the reaction yield, which was estimated by comparing the peak areas of DIB-zidovudine in the reaction mixture with that of authentic DIB-zidovudine, was 78%.

3.3.

Calibration curve, detection limit and repeatability Validation is carried out according to PDA guideline for bioanalytical method

214 215

[23].

A calibration curve was prepared by spiking blank plasma with varying

216

concentration of zidovudine.

217

peak area and zidovudine concentration over the range from 0.32 to 1336 ng mL-1.

A linear relationship (r = 0.999) was obtained between

9

Page 9 of 23

218

The slope and intercept of regression equation (mean ± standard error, n = 3) were

219

4.03×105 ± 1.5×104 and 1.1×102 ± 8.8×10, respectively.

220

zidovudine in rat plasma was 0.28 ng mL-1 (20 fmol/injection) at a signal-to-noise

221

ratio (S/N) of 3.

222

that of HPLC with UV detection [24], 3 times higher than that of HPLC with

223

electrochemical detection [25] and 3 times higher than that of HPLC with

224

electrospray ionization tandem mass spectrometry [26].

225

method was 4 times less sensitive than radio-immunoassay [27], the proposed method

226

does not require special and hazardous materials unlike radio-immunoassay.

227

Accuracy and precision of the proposed method were examined using three levels

228

(2.67, 53.4 and 802 ng mL-1) of zidovudine in rat plasma.

229

within- and between-day accuracy ranged from 91.1% to 105% with %RSD of

230

precision less than 5.2%.

231

sufficient accuracy and precision.

235 236 237 238

ip t

cr

an

us

Although the proposed

M

As shown in Table 1, the

d

Therefore, it was proved that the proposed method showed

3.4.

Determination of zidovudine in rat plasma after administration

Ac ce p

234

The sensitivity of the proposed method was 26 times higher than

te

232 233

The detection limit of

To demonstrate the practicality of the proposed method, the zidovudine

concentration in rat plasma after a single dose administration was determined. Typical chromatograms of blank rat plasma and rat plasma collected after 15 min after the administration of zidovudine (10 mg kg-1) are shown in Fig. 4 (A) and (B), respectively.

The peak of DIB-zidovudine could be detected clearly and there were

239

no interfering peaks derived from plasma components.

These results mean that

240

DIB-ET reacted selectively with zidovudine and did not react with most of biological

241

components.

242

zidovudine.

243

administration.

Figure 5 shows mean plasma concentration vs. time profiles of The zidovudine concentration in rat plasma decreased with time after The pharmacokinetic parameters (mean ± standard error, n = 3)

10

Page 10 of 23

244

were summarized as follows; AUC0→∞ 6190 ± 2290 min mg L-1; MRT 180.89 ±

245

65.71 min; T1/2 121.58 ± 47.16 min; Vd 68.02 ± 10.70 mL; CL 0.39 ± 0.15 L h-1 kg-1.

246

The results are consistent with reported results in previous study [28].

247

practicality of the proposed method was confirmed by real sample analysis.

248

consideration of high sensitivity and selectivity, the proposed method should be

249

useful for therapeutic drug monitoring of zidovudine in routine clinical practice with

250

simple procedure for sample preparation.

cr

ip t

In

us

251 4. Conclusion

an

252

The

253

M

In this study, we developed a sensitive and selective HPLC determination

254 255

method for zidovudine by fluorescent alkyne, DIB-ET as a specific fluorescence

256

derivatization reagent.

257

based on the Huisgen reaction and the DIB-zidovudine could be detected clearly on

258

the chromatogram without interference from biological components.

259

derivatization method was successfully applied to the determination of zidovudine in

261 262 263 264

d

te

Ac ce p

260

DIB-ET reacted selectively with azide group of zidovudine

rat plasma after administration.

The proposed

In the present study, the Huisgen reaction could be

subjected to fluorescent derivatization reaction for chromatographic analysis for the first time.

In further investigation, we will attempt to develop a selective

derivatization method for alkyne compounds by using fluorescent azide compound as a reagent on the basis of the Huisgen reaction.

11

Page 11 of 23

265

References

266 267

[1] G. Neurauter, S. Scholl-Bürgi, A. Haara, S. Geisler, P. Mayersbach, H. Schennch, D. Fuchs, Simultaneous measurement of phenylalanine and tyrosine by high

269

performance liquid chromatography (HPLC) with fluorescence detection, Clin.

270

Biochem. 46 (2013) 1848-1851.

cr

ip t

268

[2] X. Guo, P. Zhao, H. Wang, H. Zhang, Simple and rapid determination of thiol

272

compounds by HPLC and fluorescence detection with 1,3,5,7-tetramethyl-8-

273

phenyl-(2-maleimide) difluoroboradiaza-s-indacene, J. Chromatogr. B 879 (2011)

274

3932-3936.

an

us

271

[3] Y. Han, Z. Lv, T. Jiang, Y. Wang, Bioanalysis and pharmacokinetics of chitosan

276

ester in rabbit serum by HPLC with postcolumn fluorescence derivatization, J.

277

Chromatogr. B 845 (2007) 138-142.

[4] C.K. Zacharis, N. Raikos, N. Giouvalakis, H. Tsoukali-Papadopoulou, G.A.

d

278

M

275

Theodoridis, A new method for the HPLC determination of

280

gamma-hydroxybutyric acid (GHB) following derivatization with a coumarin

282 283 284 285

Ac ce p

281

te

279

analogue and fluorescence detection. Application in the analysis of biological fluids, Talanta 75 (2008) 356-361.

[5] R. Gatti, V. Vitellaro, High performance liquid chromatography analysis of aliphatic thiols in alimentary supplements and pharmaceuticals using menadione as a new useful derivatization reagent, Anal. Chim. Acta 804 (2013) 273-279.

286

[6] A.J.G. Mank, E.J. Molenaar, C. Gooijer, H. Lingeman, N.H. Velthorst, U.A.T.

287

Brinkman, Determination of the anticancer drug metabolite WR1065 using

288

pre-column derivatization and diode laser induced fluorescence detection, J.

289

Pharm. Biomed. Anal. 13 (1995) 255-263.

12

Page 12 of 23

290

[7] B. Mohammadi, M.B. Majnooni, P.M. Khatabi, R. Jalili, G. Bahrami, 9-Fluorenylmethyl chloroformate as a fluorescence-labeling reagent for

292

derivatization of carboxylic acid moiety of sodium valproate using liquid

293

chromatography/tandem mass spectrometry for binding characterization: A human

294

pharmacokinetic study, J. Chromatogr. B 880 (2012) 12-18.

[8] N. Kuroda, S. Sugihara, Y. Sugihara, M. Wada, N. Kishikawa, Y. Ohba, K.

cr

295

ip t

291

Nakashima, Fluorescence labeling method for aryl halides with

297

4-(4,5-diphenyl-1H-imidazol-2-yl)phenylboronic acid based on Suzuki coupling

298

reaction, J. Chromatogr. A 1066 (2005) 119-125.

us

296

[9] N. Kishikawa, C. Hamachi, Y. Imamura, Y. Ohba, K. Nakashima, Y. Tagawa, N.

300

Kuroda, Determination of haloperidol and reduced haloperidol in human serum by

301

liquid chromatography after fluorescence labeling based on the Suzuki coupling

302

reaction, Anal. Bioanal. Chem. 386 (2006) 719-724.

M

an

299

[10] N. Kishikawa, K. Kubo, S.F. Hammed, M.M. Mabrouk, A. Habib, H. Elfatatry,

304

K. Ohyama, K. Nakashima, N. Kuroda, Fluorogenic derivatization of aryl halides

305

based on the formation of biphenyl by Suzuki coupling reaction with

307 308 309 310

te

Ac ce p

306

d

303

phenylboronic acid, J. Chromatogr. A 1216 (2009) 6873-6876.

[11] L.A. Adutwum, N. Kishikawa, K. Ohyama, S. Harada, K. Nakashima, N. Kuroda, Peroxyoxalate chemiluminescence detection for the highly sensitive determination of fluorescence-labeled chlorpheniramine with Suzuki coupling reaction, Anal. Bioanal. Chem. 398 (2010) 823-829.

311

[12] N. Kishikawa, M. Ohkuma, M. Wada, K. Ohyama, R. Ikeda, K. Nakashima, N.

312

Kuroda, Labeling of alprenolol with fluorescent aryl iodide as a reagent based on

313

Mizoroki-Heck coupling reaction, J. Chromatogr. A 1218 (2011) 3002-3006.

314 315

[13] B. Letribot, R. Akué-Gédu, N.M. Santio, M. El-Ghozzi, D. Avignant, F. Cisnetti, P.J. Koskinen, A. Gautier, F. Anizon, P. Moreau, Use of copper(I) catalyzed azide

13

Page 13 of 23

316

alkyne cycloaddition (CuAAC) for the preparation of conjugated

317

pyrrolo[2,3-a]carbazole Pim kinase inhibitors, Eur. J. Med. Chem. 50 (2012)

318

304-310. [14] N. Akeroyd, B. Klumperman, The combination of living radical polymerization

ip t

319

and click chemistry for the synthesis of advanced macromolecular architectures,

321

Eur. Polym. J. 47 (2011) 1207-1231.

cr

320

[15] G. Yilmaz, H. Toiserkani, D.O. Demirkol, S. Sakarya, S. Timur, L. Torun, Y.

323

Yagci, Polysulfone based amphiphilic graft copolymers by click chemistry as

324

bioinert membranes, Mater. Sci. Eng. C 31 (2011) 1091-1097.

325

[16] Y. Shen, C. Han, S. Cai, P. Lu, Y. Wang, One-pot synthesis of

an

us

322

4(3H)-quinazolinones from azides, alkynes, anilines, and carbon monoxide,

327

Tetrahedron Lett. 53 (2012) 5671-5673.

328

M

326

[17] H.C. Kolb, K.B. Sharpless, The growing impact of click chemistry on drug discovery, Drug Discov. Today 8 (2003) 1128-1137.

330

[18] G.J. Veal, D.J. Back, Metabolism of zidovudine, Gen. Pharmacol. 26 (1995)

331

1469-1475.

333 334 335 336 337

te

Ac ce p

332

d

329

[19] M.A. Raviolo, J.M. Sanchez, M.C. Briñón, M.A. Perillo, Determination of liposome permeability of ionizable carbamates of zidovudine by steady state fluorescence spectroscopy, Colloids Surf. B 61 (2008) 188-198.

[20] M. Gerschenson, K. Brinkman, Mitochondrial dysfunction in AIDS and its treatment, Mitochondrion 4 (2004) 763-777.

[21] K. Nakashima, H. Yamasaki, N. Kuroda, S. Akiyama, Evaluation of lophine

338

derivatives as chemiluminogens by a flow-injection method, Anal. Chim. Acta 303

339

(1995) 103-107.

340 341

[22] L. Zhang, Y. Deng, Y. Li, H. Wu, S. Xu, Investigation of the pharmacokinetics and determination of cholesteryl carbonate zidovudine in rat plasma by

14

Page 14 of 23

342

non-aqueous reversed-phase high performance liquid chromatography with UV

343

detection, J. Chromatogr. B 853 (2007) 163-167.

344

[23] U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Veterinary

346

Medicine (CVM), Guidance for Industry, Bioanalytical Method Validation,

347

http://www.fda.gov/downloads/prugs/Guisdances/ucm070107.pdf (accessed 18

348

Jan., 2014).

cr

[24] G. Ramachandran, A.K. Hemanthkumar, V. Kumaraswami, S. Swaminathan, A

us

349

ip t

345

simple and rapid liquid chromatography method for simultaneous determination of

351

zidovudine and nevirapine in plasma, J. Chromatogr. B 843 (2006) 339-344.

an

350

[25] Y. Chen, Y.X. Liu, Z.D. Chen, M.L. Chen, Y. Zhu, Determination of zidovudine

353

using anion exchange chromatography with integrated pulsed amperometric

354

detection, Chin. Chem. Lett. 23 (2012) 715-718. [26] K.B. Kenney, S.A. Wring, R.M. Carr, G.N. Wells, J.A. Dunn, Simultaneous

d

355

M

352

determination of zidovudine and lamivudine in human serum using HPLC with

357

tandem mass spectrometry, J. Pharm. Biomed. Anal. 22 (2000) 967-983.

359 360 361 362

Ac ce p

358

te

356

[27] K. Peter, J.P. Lalezari, J.G. Gambertoglio, Quantification of zidovudine and individual zidovudine phosphates in peripheral blood mononuclear cells by a combined isocratic high performance liquid chromatography radioimmunoassay method, J. Pharm. Biomed. Anal. 14 (1996) 491-499.

[28] S.D. Brown, M.G. Bartlett, C.A. White, Pharmacokinetics of intravenous

363

acyclovir, zidovudine, and acyclovir-zidovudine in pregnant rats, Antimicrob.

364

Agents Chemother. 47 (2003) 991-996.

15

Page 15 of 23

365

Figure captions

366

368

Fig. 1. Fluorescence derivatization reaction of zidovudine with DIB-ET based on the Huisgen reaction.

ip t

367

369

371

Fig. 2. Chromatograms of (A) reagent blank and (B) standard solution of 5 µM

cr

370

zidovudine.

373

us

372

Fig. 3. (A) Effect of DIB-ET concentration on the peak area of zidovudine. Derivatization conditions: concentrations of zidovudine, copper (II) sulfate

375

and L-ascorbic acid were 2 µM, 120 mM and 600 mM, respectively.

376

Reaction temperature and time were 50 ˚C and 60 min, respectively.

377

(B) Effects of reaction temperature and reaction time on the peak area of

378

zidovudine. Derivatization conditions: concentrations of zidovudine, DIB-ET,

379

copper (II) sulfate and L-ascorbic acid were 2 µM, 4 mM, 40 mM and 180

380

mM, respectively.

382 383 384 385

M

d

te

Ac ce p

381

an

374

Fig. 4. Chromatograms of (A) rat plasma sample and (B) that obtained at 15 min after i.v. administration of zidovudine (10 mg kg-1).

Fig. 5. Mean plasma concentration-time profiles of zidovudine in rat plasma

386

following administration via right inguinal vein at a dose of 10 mg kg-1 to

387

Wistar male rats (data are means ± standard error, n = 3).

388

16

Page 16 of 23

388

Table1 Within- and between-day accuracy and precision of the proposed method

389

for determination of zidovudine in rat plasma.

Zidovudine -1

(ng mL )

a

Between-day (n=5)

Accuracy

Precision

Accuracy

(%)

(RSD a, %)

(%)

2.67

91.1

4.8

92.3

53.4

103

3.2

105

1.9

802

99.1

3.2

103

1.6

Relative standard deviation

ip t (RSD a, %)

cr

5.2

an

391

Precision

us

390

Within-day (n=5)

Ac ce p

te

d

M

392

17

Page 17 of 23

te

d

M

an

us

cr

ip t

Highlights A fluorescence derivatization method for determination of zidovudine is described. Zidovudine can be reacted with fluorescent alkyne based on the Huisgen reaction. The method allows sensitive and selective determination of zidovudine in plasma.

Ac ce p

392 393 394 395 396

18

Page 18 of 23

Ac

ce

pt

ed

M

an

us

cr

i

Figure 1

Page 19 of 23

Ac

ce

pt

ed

M

an

us

cr

i

Figure 2

Page 20 of 23

Ac

ce

pt

ed

M

an

us

cr

i

Figure 3

Page 21 of 23

Ac

ce

pt

ed

M

an

us

cr

i

Figure 4

Page 22 of 23

Ac

ce

pt

ed

M

an

us

cr

i

Figure 5

Page 23 of 23